01—Abstract
Summary
Summary of the 8-K filed November 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (the "Company") filed this Current Report on Form 8-K to disclose an executive compensation and employment matter under Item 5.02.
The filing states that Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. In connection with that transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement effective June 2, 2025, under which Dr. Roberts serves as Strategic Advisor through December 31, 2025.
On November 21, 2025, the Company entered into an amendment to that Amended Employment Agreement extending the term of employment for an additional 12-month period, expiring December 31, 2026. The filing describes this only briefly and refers readers to the full amendment, which is filed as Exhibit 10.1.
For investors, this is a routine executive-transition disclosure with no financial results, dollar amounts, or operational metrics stated in the filing. Its main significance is governance-related: it confirms the leadership handoff in the Chief Medical Officer role and extends Dr. Roberts's continued involvement with the Company as a strategic advisor through the end of 2026.
02—Key points
Key Highlights
- Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025.
- Dr. Roberts and the Company entered into an Amended and Restated Employment Agreement effective June 2, 2025, under which she serves as Strategic Advisor through December 31, 2025.
- On November 21, 2025, the Company entered into an amendment extending Dr. Roberts's employment term for an additional 12 months, to December 31, 2026.
- The filing provides only a brief description of the amendment; the full text is filed as Exhibit 10.1.
- No financial results, dollar compensation amounts, or percentage changes are stated in the filing.
- The filing also includes the Cover Page Interactive Data File (Exhibit 104), embedded within the Inline XBRL document.
03—Questions
Frequently Asked Questions
Who is the Company's current Chief Medical Officer?
According to the filing, Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025.
What is Dr. Roberts's role after the leadership transition?
Under the Amended and Restated Employment Agreement effective June 2, 2025, Dr. Roberts serves as Strategic Advisor through December 31, 2025.
What did the November 21, 2025 amendment change?
The amendment extended the term of Dr. Roberts's employment for an additional 12-month period, expiring December 31, 2026. The filing does not describe other terms in detail.
Where can investors find the full terms of the amendment?
The full text of the amendment is filed as Exhibit 10.1 to the Current Report on Form 8-K, and the filing states the summary is qualified in its entirety by that exhibit.
Does this filing disclose any financial impact?
The filing does not state any compensation amounts, financial results, or other financial figures related to this arrangement.
04—Continue